CDRD Ventures Inc. Announces New Partnership with Pfizer

CDRD Ventures Inc. Announces New Partnership with Pfizer 
VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 02/21/13 -- CDRD
Ventures Inc. (CVI), the commercialization vehicle of The Centre for
Drug Research and Development (CDRD), and Pfizer Inc. today announced
a strategic collaboration designed to provide new resources to
advance Canada's most innovative and therapeutically promising health
technologies towards commercialization. 
Through this collaboration, Pfizer will have the opportunity to
support mutually-selected CVI R&D projects with the goal of
commercializing the programs and resulting intellectual property.
This new collaboration follows previous investments by Pfizer Canada
Inc. into CDRD whereby a Pfizer-CDRD Innovation Fund was first
established in 2007 to support innovative projects with therapeutic
potential stemming from academic discovery. This new CVI partnership
is an extension to the original CDRD relationship, and together, the
two represent a continuum of support for health research projects,
whether they are very early projects in CDRD or more mature projects
that have been advanced into CVI. 
Natalie Dakers, President and CEO of CVI, commented, "Pfizer was our
pioneering industry partner making critical early investments in
CDRD, thus enabling its evolution to become Canada's national drug
development and commercialization centre. By now extending Pfizer's
partnership into CVI (its third such industry partnership), we have
further validated the CDRD/CVI model, and built a continuous and
robust means to support the most exciting new health technologies
through their full development cycle." 
"We are encouraged by the B.C.'s government's openness to work
collaboratively with our industry, and coupled with the great
scientific leadership coming from the province, it has resulted in
today's collaboration announcement," said John Helou, President,
Pfizer Canada. "CDRD Ventures Inc. builds on the strength of hundreds
of researchers and applies business discipline and scientific rigor
to select promising technologies for development, giving Canada and
British Columbia an edge towards a prosperous knowledge-based economy
which is critical to ensuring Canada's global competitiveness." 
"At Pfizer we know that emerging science is happening at a rapid pace
in innovation clusters throughout the world," said Uwe Schoenbeck,
Chief Scientific Officer, External R&D Innovation at Pfizer. "This
partnership with CDRD Ventures Inc is an important example of our
focus on partnering globally to identify and advance potential
therapies that can significantly improve patient lives." 
The role of CDRD is to transform promising health research
discoveries into viable commercial opportunities. CVI then in turn,
transforms those opportunities into real and measurable value, thus
providing a self-sustainability mechanism for CDRD, and providing
long-term support for the commercialization of Canadian health
research. This innovative partnership will support those efforts by
providing the necessary funding to pursue the continued
commercialization of innovative products for patients. 
About CDRD Ventures Inc. (CVI) 
CVI is the commercialization vehicle of The Centre for Drug Research
and Development (CDRD). With a first right to negotiate for any of
the technologies developed at CDRD, CVI has a continuous and
unparalleled pipeline of the most innovative and
commercially-promising pre-validated and thus de-risked technologies
in Canada. From CDRD's drug development projects and/or external
opportunities, CVI licenses select promising technologies with the
goal to further advance them to a stage where they can attract
licensing partners, form the foundation for a new spin-off company,
or secure the investment needed for clinical development. 
About The Centre for Drug Research and Development (CDRD) 
CDRD is Canada's fully-integrated national drug development and
commercialization centre, providing expertise and infrastructure to
enable researchers from leading health research institutions to
advance promising early-stage drug candidates. CDRD's mandate is to
de-risk discoveries stemming from publicly-funded health research and
transform them into viable investment opportunities for the private
sector - thus successfully bridging the commercialization gap between
academia and industry. CDRD is the only fully-integrated centre of
its kind in the country - and one of a handful in the world - with
the full expertise and infrastructure to source, evaluate, develop
and commercialize both small molecule and biologic innovative
technologies in virtually any therapeutic area. Canada's Networks of
Centres of Excellence Program has recognized CDRD as a Centre of
Excellence for Commercialization and Research (CECR).
Barry Gee
Director, Communications
CDRD Ventures Inc. (CVI) & The Centre for
Drug Research and Development (CDRD)
Press spacebar to pause and continue. Press esc to stop.